MedTrace Logo

Lateralization Performance in Chronic Low Back Pain

NCT06544850 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-08-09

No results posted yet for this study

Summary

The aim of our study was to examine the relationship between lateralization performance, two-point discrimination, kinesiophobia and pain catastrophizing in patients with chronic low back pain.

Conditions

  • Chronic Low-back Pain

Interventions

OTHER

experimental group

Oswestry Low Back Pain Questionnaire will be used to assess functional limitations in daily life activities of patients with low back pain. Recognize mobile application will be used to assess lateralization performance. Evaluation will be made with hand, foot and back modules of this application. Reaction time and accuracy given at the end of the application will be recorded. The most accurate response instruction will be given in the shortest possible time. Visual Analog Scale (VAS) will be used to measure general pain status of patients. Tampa Kinesiophobia Scale will be used to assess fear of movement. Pain catastrophizing level will be assessed with Pain Catastrophizing Scale. Two-point discrimination device will be used to assess two-point discrimination. Central Sensitization Inventory will be used for central sensitization findings.

OTHER

control group

Healthy volunteer participants who meet the inclusion criteria will be evaluated with the tests applied to the experimental group

Sponsors & Collaborators

  • Inonu University

    lead OTHER

Principal Investigators

  • YÜKSEL · Assistant researcher

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-10
Primary Completion
2024-11-01
Completion
2024-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06544850 on ClinicalTrials.gov